UK markets closed
  • NIKKEI 225

    29,222.77
    +353.86 (+1.23%)
     
  • HANG SENG

    19,922.45
    +91.93 (+0.46%)
     
  • CRUDE OIL

    87.22
    +0.69 (+0.80%)
     
  • GOLD FUTURES

    1,775.60
    -14.10 (-0.79%)
     
  • DOW

    33,971.56
    -180.45 (-0.53%)
     
  • BTC-GBP

    19,477.57
    -339.37 (-1.71%)
     
  • CMC Crypto 200

    556.98
    -15.84 (-2.77%)
     
  • ^IXIC

    12,927.97
    -174.58 (-1.33%)
     
  • ^FTAS

    4,146.49
    -19.89 (-0.48%)
     

$2 Billion Worldwide Pharmerging Industry to 2027 - Featuring Pfizer, AstraZeneca and Abbott Laboratories Among Others

·6-min read
Company Logo
Company Logo

Global Pharmerging Market

Global Pharmerging Market
Global Pharmerging Market

Dublin, July 15, 2022 (GLOBE NEWSWIRE) -- The "Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global pharmerging market reached a value of US$ 1.0 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 2.0 Billion by 2027, exhibiting a CAGR of 12.25% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth.

Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth.

Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

  • How has the global pharmerging market performed so far and how will it perform in the coming years?

  • What are the key regional markets?

  • What is the impact of COVID-19 on the global pharmerging market?

  • What is the breakup of the market based on the product?

  • What is the breakup of the market based on the indication?

  • What is the breakup of the market based on the distribution channel?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the market?

  • What is the structure of the global pharmerging market and who are the key players?

  • What is the degree of competition in the market?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Pharmerging Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Pharmaceutical
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Patented Prescription Drugs
6.1.2.2 Generic Prescription Drugs
6.1.2.3 OTC Drugs
6.1.3 Market Forecast
6.2 Healthcare
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Medical Devices
6.2.2.2 Clinical Diagnosis
6.2.2.3 Others
6.2.3 Market Forecast

7 Market Breakup by Indication
7.1 Lifestyle Diseases
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cancer and Autoimmune Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Infectious Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast

8 Market Breakup by Distribution Channel
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast

9 Market Breakup by Country

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Sanofi S.A.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Pfizer Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 AstraZeneca Plc.
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 GlaxoSmithKline Plc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.3 SWOT Analysis
13.3.5 F. Hoffmann-La Roche AG (Roche AG)
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Eli Lilly and Company
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Johnson & Johnson
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Abbott Laboratories
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Novartis AG
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Teva Pharmaceutical Limited
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financial
13.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/6tg3a5

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting